Stock vs Stock Comparison

Catalyst Pharmaceuticals, Inc. vs Eli Lilly and Company

LLY wins the Tale of the Tape 6–3.

CPRX
LLY$1064.15

🏆 Tale of the Tape

36
CPRXLLY
36.4%Profitability (Net Margin)31.7%
18.0xValuation (P/E)39.2x
21.3%Efficiency (ROIC)30.4%
5/9Health (Piotroski F)7/9
Safety (Altman Z)7.8
19.8%Growth (Rev YoY)44.7%
Risk (Sharpe 1Y)0.61
0.16xBalance Sheet (D/E)3.24x
FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCPRXLLY
Market Cap$3.8B$985.4B
P/E Ratio18.0x39.2x
Forward P/E10.0x24.8x
P/B3.77x31.65x
Dividend Yield0.63%
Beta0.720.48

Quantitative Metrics

MetricCPRXLLY
DCF Fair Value$65.94$296.11
DCF Upside-68.2%
Piotroski F5/97/9
Altman Z7.84
Beneish M-1.78-1.91
FCF Yield0.68%
Net Debt/EBITDA-2.4x1.1x
ROIC21.3%30.4%
WACC7.8%
ROIC – WACC22.5pp
Gross Margin85.2%83.0%
Net Margin36.4%31.7%
Rev Growth YoY19.8%44.7%
Sharpe (1Y)0.61
Max Drawdown 3Y
FCF Payout Ratio90%

CPRX Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

CPRX found in:

XBI0.97%
SLYG0.43%
SPSM0.22%
VTWO0.10%
VFQY0.08%
VHT0.05%
SPTM0.00%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CPRX vs LLY: Head-to-Head Analysis

Catalyst Pharmaceuticals, Inc. (CPRX) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CPRX generates a return on invested capital (ROIC) of 21.3% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

CPRX appears in 7 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CPRX or LLY?

Our quantitative analysis compares CPRX and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CPRX and LLY correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.